AAV2-BDNF gene therapy (University Of California San Diego)

N/A

Report date: 2023/10/26 17:02:30

Base Information

Drug NameAAV2-BDNF gene therapy (University Of California San Diego)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionBrain-derived neurotrophic factor modulators
TargetsBrain-derived neurotrophic factor
Therapy Area/IndicationsCognitive DysfunctionAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesThe Ohio State UniversityUniversity Of California San Diego
Inactive CompaniesN/A
Active IndicationsCognitive DysfunctionAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A